U.S. Stock Market News | Weight-loss drug Zepbound expected to be approved in Japan next year, Eli Lilly up more than 1%

智通財經
2024.10.11 15:01

週五，禮來股價震盪上行，截至發稿，上漲 1.18%，報 921.435 美元。消息面上，禮來公司首席執行官週五表示，減肥藥 Zepbound 有望明年在日本獲批。

智通財經 APP 獲悉，週五，禮來 (LLY.US) 股價震盪上行，截至發稿，上漲 1.18%，報 921.435 美元。消息面上，禮來公司首席執行官週五表示，減肥藥 Zepbound 有望明年在日本獲批。

Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.